Treatment resistant adolescent depression with upper airway resistance syndrome treated with rapid palatal expansion: a case report
© Miller et al.; licensee BioMed Central Ltd. 2012
Received: 23 May 2012
Accepted: 11 October 2012
Published: 4 December 2012
To the best of our knowledge, this is the first report of a case of treatment-resistant depression in which the patient was evaluated for sleep disordered breathing as the cause and in which rapid palatal expansion to permanently treat the sleep disordered breathing produced a prolonged symptom-free period off medication.
An 18-year-old Caucasian man presented to our sleep disorders center with chronic severe depression that was no longer responsive to medication but that had recently responded to electroconvulsive therapy. Ancillary, persistent symptoms included mild insomnia, moderate to severe fatigue, mild sleepiness and severe anxiety treated with medication. Our patient had no history of snoring or witnessed apnea, but polysomnography was consistent with upper airway resistance syndrome. Although our patient did not have an orthodontic indication for rapid palatal expansion, rapid palatal expansion was performed as a treatment of his upper airway resistance syndrome. Following rapid palatal expansion, our patient experienced a marked improvement of his sleep quality, anxiety, fatigue and sleepiness. His improvement has been maintained off all psychotropic medication and his depression has remained in remission for approximately two years following his electroconvulsive therapy.
This case report introduces the possibility that unrecognized sleep disordered breathing may play a role in adolescent treatment-resistant depression. The symptoms of upper airway resistance syndrome are non-specific enough that every adolescent with depression, even those responding to medication, may have underlying sleep disordered breathing. In such patients, rapid palatal expansion, by widening the upper airway and improving airflow during sleep, may produce a prolonged improvement of symptoms and a tapering of medication. Psychiatrists treating adolescents may benefit from having another treatment option for treatment-resistant depression.
Treatment-resistant depression is an all-too-common occurrence among adolescents . Approximately 40 percent of younger people diagnosed and being treated for depression do not respond to either serotoninergic medication or cognitive behavioral therapy. These adolescents experience impaired functioning at home and at school with increased risk of substance misuse, hospitalization and suicide, the third leading cause of death in adolescence . Both the psychological and physical suffering and the lost education and socialization make treatment-resistant depression a costly disorder for the patients, their families and society.
In the following report, we present the case of a man with treatment-resistant depression whose depression and associated symptoms have been in remission for approximately two years after the diagnosis of upper airway resistance syndrome (UARS) treated with rapid palatal expansion (RPE).
Our patient was an 18-year-old Caucasian man with a history of anxiety and depression managed by a psychiatrist since age 10 years. At the time his present psychiatrist took over his care, our patient, then aged 15 years, was most compromised by anxiety with frequent panic attacks and constant manifestations of anxious arousal with tachycardia, lightheadedness and sweaty palms. Our patient was also agitated and hypervigilant, feeling bullied by his schoolmates; symptoms that were exacerbated by going to school and socializing. As a result, our patient completed his last two years of high school being tutored at home. Depression, although present, was a secondary problem. Our patient was treated with serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antipsychotics, benzodiazepines and l-methylfolate, all without satisfactory control of his symptoms. At the age of 17 years, our patient’s depression worsened. He became sad and anhedonic with sleep complaints and vague threats of self-harm. His anxiety and hypervigilance continued. He was treated with lithium, fluoxetine, venlafaxine, lamotrigine and quetiapine, all without consistent improvement.
Because of the failure of medication to improve our patient’s symptoms, his psychiatrist had him evaluated by a psychiatrist specializing in electroconvulsive therapy (ECT). He received a course of ECT of three weekly treatments for eight weeks. The treating psychiatrist monitored our patient’s response and at the conclusion of ECT, our patient rated his own mood at ‘nine out of a possible 10’, 10 being the best mood. During our patient’s ECT, his parents spoke with a physician at the local sleep disorders center who suggested that, at the conclusion of his ECT, our patient be evaluated for sleep disordered breathing (SDB). One month following ECT, our patient came to our sleep disorders center for a consultation.
Our patient had mild difficulty falling asleep, taking 10 to 30 minutes. While awaiting sleep, he experienced some intense thoughts, but no restless legs. He had no trouble staying asleep. According to his parents, our patient did not snore or stop breathing, but tossed and turned throughout the night. After 10 to 12 hours of sleep, he would awaken unrefreshed with a headache and with his bed in disarray. He evaluated himself as mildly sleepy (a score of 7/24 on the Epworth sleepiness scale) with moderate/severe fatigue (a score of 5.2/7.0 on the fatigue severity scale) and somatic arousal (a score of 31/85 on the Mood and Anxiety Symptoms Questionnaire (MASQ) anxious arousal subscale, reflecting the somatic manifestations of increased sympathetic tone: for example, palpitations, sweating, tremulousness, frequent urination, feeling hot).
Our patient’s medications included lamotrigine (50mg) and quetiapine (50mg) for his anxiety, esomeprazole for gastro-esophageal reflux, cetirizine for seasonal nasal allergies and metformin for hyperglycemia.
On physical examination, our patient was found to be obese. He was 1.73m in height and weighed 101.15kg with a body mass index of 33.9kg/m2. His blood pressure of 140/85 and his pulse of 88 beats/min were both elevated. His upper airway examination revealed a narrow maxillary arch with a high arched palate, an elongated soft palate and uvula, a Mallampati score of 3 and a neck circumference of 40.64cm. The tonsils had not been removed but were not visible. The remainder of his physical examination was unrevealing.
Based upon our patient’s history of borderline sleep-onset insomnia, restless, non-restorative sleep associated with a morning headache and moderate to severe fatigue, and his sleep study demonstrating obstructive SDB below the threshold for a diagnosis of obstructive sleep apnea, a diagnosis of UARS was made. As treatment, our patient was referred to an orthodontist for RPE, an orthodontic treatment that has been shown to relieve mild obstructive sleep apnea in both children  and adults .
Two years following his ECT, our patient remained without symptoms of depression, chronic anxiety or sleepiness/fatigue off psychotropic medication. He no longer requires home tutoring, attends college and is doing well scholastically.
Our patient’s case of treatment-resistant depression responding to treatment of UARS with RPE is unusual from several perspectives. First, our patient was suspected of having SDB despite having no history of snoring or witnessed apnea. Second, RPE was utilized to treat our patient’s UARS even though he had no cross-bite, the condition for which RPE was developed. Third, following RPE, our patient’s apnea hypopnea index and frequency of RERAs (indices of SDB severity) did not change, yet his anxiety, sleepiness and fatigue improved markedly and his depression remained in remission without medication. What is the evidence that his UARS improved and how did that improvement lead to a change in his symptoms? These issues will be discussed below.
To consider that unrecognized SDB may underlie depression is not standard medical practice. Yet, increasing evidence suggests that SDB and depression are associated in both children  and adults . Furthermore, in children, the association does not appear to depend upon the severity of pharyngeal collapse during sleep. A history of pronounced snoring is enough to consider a person at increased risk for depression . Therefore, our patient’s diagnosis of UARS would put him at increased risk for depression.
UARS is an association between very mild pharyngeal collapse during sleep, a severity of collapse that does not meet the clinical threshold for a diagnosis of sleep apnea, and daytime sleepiness/fatigue . Sleep-onset insomnia is also frequently associated . While collapse of the pharyngeal airway during sleep occurs in all patients with UARS, not all patients with UARS snore audibly . Therefore, anyone with sleep-onset insomnia, restless sleep and daytime sleepiness/fatigue, symptoms that are common among depressed individuals, may have UARS.
Our treatment of our patient’s UARS with RPE is consistent with the literature demonstrating an improvement in mild sleep apnea among children treated with RPE . However, RPE to treat an adolescent with SDB in the absence of a cross-bite has not been previously reported. We reasoned that our patient’s Angle’s Class I bite was not acceptable in the presence of UARS and treatment resistance depression, so widening his nasal airway while tilting the mandibular teeth outward to correct his bite was needed, and successfully achieved.
The idea that RPE improved our patient’s inspiratory airflow alleviating UARS is central to this case report. But what is the evidence that airflow improved? Inspiratory airflow limitation (IFL) persisted in our patient’s second polysomnogram and the airflow signal, which was uncalibrated, did not allow for quantitative comparisons. While the direct evidence for increased inspiratory airflow is missing, the equation for flow through the upper airway during IFL (maximal flow=-(pharyngeal critical pressure)/upstream resistance, where the upstream airway is from the nares to the point of pharyngeal collapse) implies that widening the nasal airway led to an increase in maximal inspiratory airflow through decreased nasal resistance . The resolution of the paradoxical thoracoabdominal motion observed during polysomnography after RPE provides indirect evidence for improved inspiratory airflow that decreased inspiratory effort. Therefore, without direct evidence, it is reasonable to conclude that RPE improved our patient’s inspiratory airflow despite the persistence of IFL during sleep.
While an association between SDB and depression is increasingly recognized, the mechanism for that association is unclear. Although previous investigators have hypothesized contributions from fragmented sleep, hypoxemia and hypercapnia [5, 6], RPE did not decrease our patient’s sleep fragmentation nor did it prevent hypoxemia, which was not present before treatment. An alternative hypothesis is that, for our patient, mild IFL during sleep was a stressor that chronically activated his brain’s limbic system, sympathetic nervous system and hypothalamic-pituitary-adrenal axis . Such an hypothesis can explain the mild sleep-onset insomnia, increased vigilance during sleep, anxiety, sleepiness/fatigue and depression experienced by our patient (symptoms of chronic stress [4, 11]) while explaining his growth and improved glycemic control (increased growth hormone and decreased cortisol ) following RPE.
A further clue to understanding the resolution of our patient’s depression and anxiety is found in a comparison of his questionnaire data and polysomnography before and after treatment. Before treatment, our patient had increased sympathetic nervous system activity manifest as an increased score on the MASQ anxious arousal subscale and an increased heart rate during sleep. After RPE, our patient’s score on the MASQ anxious arousal subscale was minimized (Figure 3) and his heart rate during sleep decreased. Furthermore, before treatment, our patient’s polysomnogram demonstrated marked periodic leg movement disorder that was gone following treatment. Periodic leg movement disorder is believed to reflect central nervous system dopamine deficiency . Thus, treatment of our patient’s UARS may have altered his central catecholamine balance decreasing sympathetic nervous system mediators while increasing central dopamine. Increased central dopamine activity has been associated with a decreased tendency toward depression  and anxiety  in humans.
Because our patient’s depression was treated with ECT and remitted before he underwent RPE, we are left with some uncertainty about the contribution of RPE toward our patient’s present affective state. How do we know our patient is without symptoms because of RPE? Although there is limited information concerning the effect of ECT in adolescents, in the one case series of 10 patients treated with ECT, most were maintained on one or two antidepressants post-ECT and three of the nine followed for one year relapsed . Our patient’s psychiatrist has treated one other depressed adolescent with ECT. That patient underwent a remission that was maintained with an antidepressant for one year before relapse. In the literature, there is no discussion of the effect of ECT on the sleep complaints or anxiety that may be associated with major depression. In our patient’s case, both were present after ECT and resoloved after RPE.
The sustained improvement of this adolescent’s treatment-resistant depression, anxiety and fatigue/sleepiness after RPE is a clinical finding of enormous importance to psychiatrists managing depression and their patients. The symptoms of SDB can be so non-specific (fatigue, insomnia, restless sleep) that every depressed adolescent may have them. Indeed, the prevalence of IFL during sleep among depressed adolescents is unknown. However, given the physically benign nature of RPE as a treatment and the control that may be obtained over symptoms, we believe that evidence of SDB should be sought in every depressed adolescent and, when present, treated and the resulted should be documented.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Maalouf FT, Atwi M, Brent DA: Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety. 28: 946-954.Google Scholar
- Pirelli P, Saponara M, Guilleminault C: Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep. 2004, 27: 761-766.PubMedGoogle Scholar
- Cistulli PA, Palmisano RG, Poole MD: Treatment of obstructive sleep apnea syndrome by rapid maxillary expansion. Sleep. 1998, 21: 831-835.PubMedGoogle Scholar
- Voss U: Functions of sleep architecture and the concept of protective fields. Rev Neurosci. 2004, 15: 33-46.PubMedGoogle Scholar
- Crabtree VM, Varni JW, Gozal D: Health-related quality of life and depressive symptoms in children with suspected sleep-disordered breathing. Sleep. 2004, 27: 1131-1138.PubMedGoogle Scholar
- Wheaton AG, Perry GS, Chapman DP, Croft JB: Sleep disordered breathing and depression among U.S. adults: National Health and Nutrition Examination Survey, 2005–2008. Sleep. 2012, 35: 461-467.PubMedPubMed CentralGoogle Scholar
- del Campo Matías F, Ruiz Albi T, Zamarrón Sanz C: Upper Airway Resistance Syndrome - A Twenty-Five Years Experience, Sleep Disorders. Edited by: Idzikowski C. 2012, InTech, Available from: http://www.intechopen.com/books/sleep-disorders/upper-airway-resistance-syndrome-a-twenty-five-years-experience Google Scholar
- Gold AR, Dipalo F, Gold MS, O'Hearn D: The symptoms and signs of upper airway resistance syndrome: a link to the functional somatic syndromes. Chest. 2003, 123: 87-95. 10.1378/chest.123.1.87.View ArticlePubMedGoogle Scholar
- Kristo DA, Lettieri CJ, Andrada T, Taylor Y, Eliasson AH: Silent upper airway resistance syndrome: prevalence in a mixed military population. Chest. 2005, 127: 1654-1657. 10.1378/chest.127.5.1654.View ArticlePubMedGoogle Scholar
- Gold AR, Schwartz AR: The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Chest. 1996, 110: 1077-1088. 10.1378/chest.110.4.1077.View ArticlePubMedGoogle Scholar
- Gold AR: Functional somatic syndromes, anxiety disorders and the upper airway: a matter of paradigms. Sleep Med Rev. 2011, 15: 389-401. 10.1016/j.smrv.2010.11.004.View ArticlePubMedGoogle Scholar
- Natarajan R: Review of periodic limb movement and restless leg syndrome. J Postgrad Med. 2010, 56: 157-162. 10.4103/0022-3859.65284.View ArticlePubMedGoogle Scholar
- Porcelli S, Drago A, Fabbri C, Serretti A: Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2011, 35: 1532-1543. 10.1016/j.pnpbp.2011.03.005.View ArticlePubMedGoogle Scholar
- Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Gründer G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A: Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci. 2008, 11: 1381-1382. 10.1038/nn.2222.View ArticlePubMedGoogle Scholar
- Strober M, Rao U, DeAntonio M, Liston E, State M, Amaya-Jackson L, Latz S: Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy. Biol Psychiatry. 1998, 43: 335-338. 10.1016/S0006-3223(97)00205-9.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.